Related Experiment Videos
Vitamin D analogs: from renal bone disease to osteoporosis
1WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, United Kingdom.
Abstract:
The history of the use of vitamin D metabolites and analogs in clinical medicine began with their use in renal bone disease following the appreciation that the kidney is the major site of the 1 alpha-hydroxylase of vitamin D. In the presence of advanced renal failure, production of calcitriol is impaired and treatment is viewed conceptually as a hormone replacement therapy. Since then, there has been much interest in the rationale for the use of such compounds in osteoporosis. Arguments have been variously forwarded that osteoporosis is in part due to either a defective 1 alpha-hydroxylase occurring at menopause or in later life or to target tissue resistance to calcitriol; some argue that disturbances in vitamin D metabolism are irrelevant to osteoporosis, being either a consequence of aging or a result, not a cause, of osteoporosis itself. This paper reviews these various issues and explores the differences and similarities between the pathogenesis of renal bone disease and osteoporosis.
Insights
This review explores vitamin D metabolites in treating renal bone disease and osteoporosis. It examines the role of 1 alpha-hydroxylase and calcitriol in bone health and disease pathogenesis.
Area of Science:
- Endocrinology
- Nephrology
- Bone Metabolism
Background:
- The kidney's role in vitamin D activation via 1 alpha-hydroxylase is crucial for managing renal bone disease.
- Calcitriol (active vitamin D) production is impaired in renal failure, necessitating hormone replacement therapy.
- The use of vitamin D metabolites and analogs has expanded beyond renal bone disease to include osteoporosis.
Purpose of the Study:
- To review the historical use of vitamin D metabolites and analogs in clinical medicine.
- To explore the rationale and evidence for using vitamin D compounds in osteoporosis management.
- To compare and contrast the pathogenesis of renal bone disease and osteoporosis.
Main Methods:
- Literature review of studies on vitamin D metabolism and bone diseases.
- Analysis of arguments regarding vitamin D's role in osteoporosis pathogenesis.
- Comparative analysis of renal bone disease and osteoporosis.
Main Results:
- Vitamin D metabolite use originated from understanding kidney's role in vitamin D activation for renal bone disease.
- Debate exists on whether osteoporosis involves defective 1 alpha-hydroxylase, calcitriol resistance, or if vitamin D disturbances are secondary.
- Similarities and differences in pathogenesis between renal bone disease and osteoporosis are explored.
Conclusions:
- Vitamin D metabolite therapy is established for renal bone disease as hormone replacement.
- The role of vitamin D in osteoporosis pathogenesis remains a subject of ongoing research and debate.
- Understanding vitamin D's complex interactions is key for effective bone disease management.